Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comprehensive Evaluation of Drugs for Methicillin-Resistant Staphylococcal Infections
ChiCTR2600125045Phase 4Completed
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- May 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin, norvancomycin, teicoplanin, linezolid and daptomycin in Gram-positive bacterial infection, Staphylococcus aureus infection, Staphylococcosis and 2 more (4 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Clinical effective rate at end of treatment. Started May 2026; status: completed.
02
Drugs
vancomycinnorvancomycinteicoplaninlinezoliddaptomycin
03
Conditions
Gram-positive bacterial infectionStaphylococcus aureus infectionStaphylococcosisstreptococcal infectionenterococcal infection
Beyond the preview
Go deeper on ChiCTR2600125045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125045.